Entera Bio Ltd.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company that develops oral tablet formulations of peptides and protein replacement therapies. The company utilizes its proprietary delivery platform to stabilize large peptides in the gastrointestinal tract and support absorption into the bloodstream. Its drug pipeline includes EB613, an oral bone-building tablet candidate for postmenopausal osteoporosis, as well as EB612 for hypoparathyroidism. The company also advances early-stage oral programs for obesity, metabolic disorders, and rare gastrointestinal diseases. Its target consumers are patients living with chronic conditions that typically require frequent injections.

Entera Bio is headquartered in Jerusalem, Israel, where it maintains office, research, and laboratory spaces. As a development-stage enterprise, the company conducts preclinical research and clinical trials across multiple programs, with its lead candidate tested in hundreds of clinical trial participants. The company operates through its Israeli organization alongside a consolidated subsidiary and manages operations across domestic and foreign jurisdictions.

Summary of the business section of Entera Bio's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2024, we had a total of 20 employees, of whom 18 are full-time employees all based in Israel.”